Navigation Links
Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Date:5/27/2009

THE WOODLANDS, Texas, May 27 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving oral presentations on two of its clinical-stage drug development programs: LX1031, an oral drug candidate for the treatment of irritable bowel syndrome (IBS), and LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The presentations will take place at Digestive Disease Week (DDW) in Chicago, Illinois on Sunday, May 31 and Monday, June 1, respectively. DDW is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. LX1031 is currently in a Phase 2 clinical trial in patients with non-constipating IBS, and LX1032 is entering a Phase 2 study in patients with carcinoid syndrome.

For more information on these programs and to download both presentations (available after June 1), please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and LX1032 and the potential therapeutic and commercial potential of LX1031 and LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... UK (PRWEB) , ... September 21, 2017 , ... ... a QuintilesIMS company, who enable the world’s most progressive pharma and biotech organizations ... clinical trials at top pharma and biotech events in Q4. , DrugDev will ...
(Date:9/21/2017)... ... 21, 2017 , ... Biorez, Inc. , a regenerative ... Entrepreneur in Residence at Medtronic, Inc., to serve as an Independent Director on ... for anterior cruciate ligament (ACL) reconstruction that is designed to stabilize the knee ...
(Date:9/20/2017)... PA and College Station, TX (PRWEB) , ... ... ... IPS-Integrated Project Services, LLC (IPS), a leading global provider of engineering, ... Inc. the leading provider of prefabricated cleanrooms, today announced the unveiling of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, a leading think ... technologies, announced the winners for the 2017 Foresight Institute Feynman Prizes.These are given ... manufacturing. , Established in 1993 and named in honor of pioneer physicist Richard ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):